Energy expenditure and anthropometric measurements in new users of depot medroxyprogesterone acetate
Keywords:
Antropometry, Contraception, Energy metabolism, Medroxyprogesterone, Body weightAbstract
Objective
The objective of this study was to assess energy expenditure and the anthropometric profile of women during the first year of use of depot medroxyprogesterone acetate contraception.
Methods
This prospective study included healthy non-obese women who had never used depot-medroxyprogesterone acetate and did not have a history of weight fluctuations. The women were divided into two groups composed of 28 depot medroxyprogesterone acetate users and 24 copper intrauterine device (TCu380A) users. They were paired for age (+1 year) and body mass index (+1 kg/m2). The following variables were used: sociodemographic characteristics (age, ethnicity, smoking status, alcohol consumption, physical activity, economic class, and education level), weight (kg), body max index, resting and total energy expenditure, waist and hip circumferences (cm), and waist-to-hip ratio.
Results
The age of the women studied ranged from 20-39 years. The mean values of age/body mass index ratio were 29.6 (SD=+5.2) years/23.9 (+3.6 kg/m2) in the depot medroxyprogesterone acetate group and 28.6 (SD=+5.2) years/24.5 (+2.7 kg/m2
) in the intrauterine device group. After conducting repeated measures analysis of variance, the users of depot edroxyprogesterone acetate showed weight gain of 2.2 kg, and those in the intrauterine device group showed weight loss of 0.2 kg without statistically significant difference between the groups. There were no significant differences between the other variables.
Conclusion
There were no changes in weight, anthropometric measurements, and energy expenditure in the young and healthy women during the first year of use of depot medroxyprogesterone acetate contraception. Guidelines and recommendations for a healthy lifestyle to avoid changes in the anthropometric measurements are important for weight control in users of contraceptive methods.
References
Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust. 1981; 1(1 Suppl.):3-19.
Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data. 2004; (350):1-36.
Infoplease. Prevalence of contraceptive use in selected countries [cited 2014 Sept 21]. Available from: http://www.infoplease.com/ipa/A0193123. html
Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr. 2001; 73(1):19-26.
Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and centraldistribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes. 2005; 29(10): 1252-8.
Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007; 75(4):261-7.
Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F. Depot medroxyprogesterone acetate: An update. Arch Gynecol Obstet. 2008; 278(1): 1-12. http://dx.doi.org/10.1007/s00404-007-0 497-z
Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception. 1980; 22(6):605-22.
Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009; 200(3):329.e1-8. http://dx.doi.org/10.1016/j.ajog. 2008.12.052
Pelkman C. Hormones and weight change. J Reprod Med. 2002; 47(9):791-4.
Associação Brasileira de Empresas de Pesquisa. Critério de classificação econômica. São Paulo: Abep; 2010 [acesso 2011 maio 2]. Disponível em: http://www.abep.org/novo/Utils/FileGenerate. ashx?id=46
Ford ES, Kohl HW 3rd, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res. 2005; 13(3):608-14.
World Health Organization. Global recommendations on physical activity for health. Geneva: WHO; 2011.
World Health Organization. Physical status: The use and interpretation of anthropometry. Technical Report Series, nº 854. Geneva: WHO; 1995.
Frankenfield DC, Muth ER, Rowe WA. The Harris Benedict studies of human basal metabolism: History and limitations. J Am Diet Assoc. 1998; 98(4):439-45.
Isosaki M, Cardoso E, Oliveira A. Manual de dietoterapia e avaliação nutricional: serviço de nutri ção e dietética do Instituto do Coração - HCFMUSP. 2ª ed. São Paulo: Atheneu; 2009.
Friendly M. From SAS System for Statistical Graphics. Version 1.2. Cary (NC): SAS Institute Inc.; 1995 (cited 2014 Apr 18]. Available from: http:// www.yorku.ca/SCS/sasmac/fpower.html
Vickey Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013; 88(4):503-8. http://dx.doi. org/10.1016/j.contraception.2013.03.004
Haider S, Darney PD. Injectable contraception. Clin Obstet Gynecol. 2007; 50(4):898-906.
Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol. 2009; 114(2):279-84. http://dx.doi.org/10.1097/A OG.0b013e3181af68b2
Pariani S, Heer DM, Van Arsdol MD Jr. Does choice make a difference to contraceptive use? Evidence from east Java. Stud Fam Plann. 1991; 22(6):384-90.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Priscilla de Nazaré Silva dos SANTOS, Marina SIDER, Waleska Oliveira MODESTO, Maria Valeria BAHAMONDES, Luis BAHAMONDES, Arlete FERNANDES
This work is licensed under a Creative Commons Attribution 4.0 International License.
